PFO
REGN icon

Pathstone Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

Pathstone Family Office’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$4.68M Buy
5,649
+2,383
+73% +$1.87M 0.04% 285
2023
Q2 		$2.32M Buy
3,266
+100
+3% +$77.1K 0.03% 294
2023
Q1 		$2.64M Sell
3,166
-5,470
-63% -$4.13M 0.04% 246
2022
Q4 		$5.84M Buy
8,636
+1,234
+17% +$911K 0.05% 257
2022
Q3 		$5.15M Buy
7,402
+6,249
+542% +$3.93M 0.05% 226
2022
Q2 		$681K Buy
1,153
+40
+4% +$26K 0.02% 459
2022
Q1 		$802K Buy
1,113
+85
+8% +$53.8K 0.02% 391
2021
Q4 		$649K Buy
1,028
+552
+116% +$339K 0.02% 455
2021
Q3 		$288K Sell
476
-35
-7% -$21.7K 0.01% 690
2021
Q2 		$285K Buy
511
+6
+1% +$3.04K 0.01% 663
2021
Q1 		$239K Buy
505
+161
+47% +$78.4K 0.01% 554
2020
Q4 		$166K Buy
344
+242
+237% +$131K 0.01% 287
2020
Q3 		$57K Hold
102
– – 0.01% 352
2020
Q2 		$63K Sell
102
-20
-16% -$11.4K 0.01% 283
2020
Q1 		$60K Sell
122
-16
-12% -$6.6K 0.01% 276
2019
Q4 		$518K Buy
138
+38
+38% +$12.8K 0.01% 290
2019
Q3 		$28K Hold
100
– – ﹤0.01% 356
2019
Q2 		$31K Sell
100
-21
-17% -$6.99K ﹤0.01% 387
2019
Q1 		$50K Buy
121
+100
+476% +$41.2K 0.01% 305
2018
Q4 		$8K Buy
+21
New +$7.69K ﹤0.01% 349
2017
Q2 		– Sell
-3
Closed -$1K – 593
2017
Q1 		$1K Buy
+3
New +$1.11K ﹤0.01% 506
2013
Q3 		– Sell
-47
Closed -$11K – 399
2013
Q2 		$11K Buy
+47
New +$10.9K 0.01% 236

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pathstone Family Office's REGN Position: Q3 2023 in Review

Pathstone Family Office increased its Regeneron Pharmaceuticals (REGN) stake by 73% in Q3 2023, buying an estimated $1.87M and bringing the position to 5,649 shares worth $4.68M. The position accounts for 0.04% of the portfolio, ranked #285.

Pathstone Family Office first reported a position in REGN in Q2 2013 and has held it in 22 quarters since. The position peaked at $5.84M in Q4 2022. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Pathstone Family Office held 5,649 shares of Regeneron Pharmaceuticals worth $4.68M as of Q3 2023.
  • Pathstone Family Office bought 2,383 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $1.87M.
  • Regeneron Pharmaceuticals made up 0.04% of Pathstone Family Office's portfolio in Q3 2023, its #285 holding.
  • Pathstone Family Office first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 22 quarters since.
  • Pathstone Family Office's Regeneron Pharmaceuticals position peaked at $5.84M in Q4 2022.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.